Search

Your search keyword '"Travis S"' showing total 108 results

Search Constraints

Start Over You searched for: Author "Travis S" Remove constraint Author: "Travis S" Journal journal of crohn's and colitis Remove constraint Journal: journal of crohn's and colitis
108 results on '"Travis S"'

Search Results

2. DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial

3. OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial

6. P285 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: European and US Patient and Health Care Professional Perspectives on the Broad Impact of Bowel Urgency in Ulcerative colitis

7. Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems

8. P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

9. OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial

10. P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey

12. P696 Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

15. P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index

16. DOP02 Single cell RNA sequencing of Ulcerative Colitis and Crohn's Disease tissue samples informs the selection of Triggering Receptors Expressed on Myeloid Cells 1 (TREM1) as a target for the treatment of Inflammatory Bowel Diseases

17. P802 Relationships between validated clinical, endoscopic and histological indices in ulcerative colitis

20. OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial

22. P494 Can Patients Monitor Response To Ustekinumab In The Real World?

23. P371 Using digital monitoring during the COVID pandemic to streamline outpatient appointments

24. DOP13 Artificial Intelligence (AI) in endoscopy - Deep learning for detection and scoring of Ulcerative Colitis (UC) disease activity under multiple scoring systems

25. P198 Practical deep learning tool for the scoring of ulcerative colitis disease activity in central reading

26. DOP09 Mirikizumab-induced transcriptome changes in patient biopsies at Week 12 are maintained through Week 52 in patients with Ulcerative Colitis

28. P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study

31. P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?

34. OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

36. DOP11 Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis

41. Th1 and innate lymphoid cells accumulate in primary sclerosing cholangitis-associated inflammatory bowel disease

44. OP015 Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM

45. P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)

47. P262 New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC)

Catalog

Books, media, physical & digital resources